Novartis Q3 Results - Q3 Top Pharma Company Earnings Reports

View Novartis' Q3 Earnings Report

FiercePharma says: Novartis boosted its full-year sales forecast, buoyed by rising sales of cancer treatment Gleevec, plus new meds for eye disease (Lucentis), brittle bones (Reclast), and high blood pressure (Exforge). Recently introduced products accounted for $1.3 billion in Q3 net sales. Net income came in at $2.1 billion on $11 billion in sales; analysts said things are "falling into place" at the company. Read more...

Highlights

  • Net sales of USD 31.3 billion rise 8% in local currencies (lc), led by double-digit expansion in Pharmaceuticals
  • Operating income of USD 7.3 billion up 1%, but advances 11% in constant currencies and excluding exceptional items
  • Net income of USD 6.1 billion down 8% due to negative currency impact, Alcon-related financing costs and USD 189 million of associated companies charges; but net income in constant currencies rises 2%
  • Basic EPS: USD 2.69 in first nine months of 2009 vs. USD 2.93 in 2008
  • Free cash flow before dividends advances 20% to USD 6.1 billion
  • Progress in innovation: 2009 approvals for Afinitor (US/EU), Ilaris (US) and H1N1 pandemic flu vaccines; positive Phase III data for QAB149 (COPD) and FTY720 (MS)
  • Novartis on track for record sales and earnings in constant currencies in 2009

Check out Novartis' current earnings estimates from CNN Money

Novartis' Website: http://www.novartis.com

Novartis Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.